Dav Sub v. Qliqsoft: Secure Healthcare Messaging Patent Dispute Settles in 342 Days
Dav Sub, Inc. asserted US7426730B2 — a patent covering secure messaging and communication technology — against Qliqsoft’s suite of healthcare texting, virtual visit, chatbot, and telehealth products. Filed in the Northern District of Texas in November 2023, the case reached a confidential settlement just under a year later, before any merits ruling was issued.
Secure Telehealth Messaging Patent Reaches Pre-Trial Settlement in Texas
In November 2023, Dav Sub, Inc. filed a patent infringement action against Qliqsoft, Inc. in the Northern District of Texas (Judge Ed Kinkeade presiding), asserting US7426730B2 against Qliqsoft’s commercial healthcare communication products — specifically its secure texting platform, secure virtual visits service, healthcare chatbot offering, and broader telehealth software systems. The asserted patent, filed under application number US10/125794, relates to secure messaging and communication technology, a domain that sits at the core of Qliqsoft’s product portfolio.
The case resolved via settlement approximately 342 days after filing. On 16 October 2024, Judge Kinkeade issued an administrative closure order after being notified the parties had settled, directing submission of dismissal papers within 60 days. Notably, the order expressly stated that it does not constitute a dismissal or disposition of the case, preserving the ability of either party to reopen proceedings. The settlement terms are not disclosed in the public record.
A resolution within roughly 11 months suggests the parties may have reached a commercial accommodation — potentially a licensing arrangement — before significant litigation costs accumulated at the district court level. No claim construction order, summary judgment ruling, or trial verdict was entered, leaving the validity and precise scope of US7426730B2 unadjudicated. The absence of any public terms means the downstream implications for the broader healthcare messaging sector remain opaque.
Filing to Case Settled in 342 days
342 days — resolved faster than the median U.S. district court patent case (~2–3 years)
Case settled: what the administrative closure order means for both parties
Administrative closure is not a dismissal — the case remains latent
Judge Kinkeade’s order explicitly states the closure is not a dismissal or disposition. The parties were directed to file formal dismissal papers within 60 days. Until those papers are filed, the case technically remains capable of being reopened. This is standard Northern District of Texas practice following a settlement notification, and the clerk’s preparation of a Patent Office report is a routine administrative step.
Procedural settlement closurePublic record is silent on whether dismissal will be with or without prejudice
The administrative closure order does not specify whether the forthcoming dismissal papers will be filed with or without prejudice. A dismissal with prejudice bars Dav Sub from re-asserting the same claims against Qliqsoft on the same patent. A dismissal without prejudice would leave that door open. Patent practitioners should note this distinction: the public record as it stands cannot confirm which form the final dismissal will take, and settlement agreements are typically confidential.
Prejudice status unconfirmedDav Sub avoids validity challenge — US7426730B2 remains unadjudicated
By settling before claim construction or trial, Dav Sub preserved the patent’s unadjudicated status. No court has ruled on validity, enforceability, or the scope of US7426730B2’s claims. This is strategically significant: the patent can potentially be asserted against other parties in the healthcare communications space without an adverse merits ruling on record. Whether a licensing payment was secured is not publicly known.
Patent validity preservedQliqsoft exits litigation without an invalidity finding — but at undisclosed cost
Qliqsoft’s entire core product suite — secure texting, virtual visits, chatbots, and telehealth platforms — was named in the complaint, creating broad commercial exposure. Settling removes immediate litigation risk but likely involves either a licensing payment or product design concessions, neither of which is publicly confirmed. Qliqsoft’s three-counsel defense team (Hilgers Graben PLLC) suggests the defendant took the threat seriously and mounted a substantive response before resolution.
Commercial exposure resolved privatelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Dav Sub, Inc. | Company | Patent assertion entity — holder of US7426730B2 covering secure messaging technologySearch in Eureka ↗ |
| Defendant | Qliqsoft, Inc. | Company | Qliqsoft, Inc. — provider of secure texting, telehealth, and healthcare chatbot platformsSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth Patrick Babb | Attorney | Counsel for Dav Sub, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fox Rothschild LLP | Law Firm | Representing Dav Sub, Inc.Search in Eureka ↗ |
| Defendant counsel | Grant Kojis Schmidt | Attorney | Counsel for Qliqsoft, Inc.Search in Eureka ↗ |
| Defendant counsel | Jon B. Hyland | Attorney | Counsel for Qliqsoft, Inc.Search in Eureka ↗ |
| Defendant counsel | Theodore Druce Kwong | Attorney | Counsel for Qliqsoft, Inc.Search in Eureka ↗ |
| Defendant law firm | HILGERS, GRABEN PLLC | Law Firm | Representing Qliqsoft, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Ed Kinkeade | Judge | Texas Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s administrative closure order, entered 16 October 2024, is procedural rather than substantive — it reflects the parties’ notification of settlement and directs the filing of dismissal papers within 60 days. The order expressly disclaims any effect as a dismissal or disposition, meaning no merits ruling on infringement, validity, or claim scope was issued. The instruction to prepare a Patent Office report is standard administrative procedure. The legal and commercial weight of this case’s resolution lies entirely in the undisclosed private settlement agreement between the parties.
US7426730B2 — Secure Messaging and Communication Technology
US7426730B2, filed under application number US10/125794, relates to secure messaging and communication technology — broadly applicable to any networked system managing authenticated, encrypted message exchange between users. In the context of this litigation, Dav Sub mapped its claims to Qliqsoft’s entire healthcare communication stack: secure texting, virtual clinical visits, AI-driven chatbots, and multi-channel telehealth platforms. The patent’s application date places its inventive priority well before the modern telehealth SaaS market matured, which may inform its claim breadth.
Secure messaging infrastructure has become foundational to HIPAA-compliant healthcare communication, making patents in this space strategically valuable to holders and commercially threatening to SaaS vendors. US7426730B2 has not been adjudicated for validity or claim scope in this case, leaving it as a live asset. Any company operating in the clinical messaging, care-team communication, or patient engagement space — particularly those using session-based or asynchronous secure chat architectures — should consider this patent when evaluating their IP risk profile.
Should your healthcare messaging platform run an FTO against US7426730B2?
If your organisation develops or commercialises secure clinical messaging, telehealth platforms, healthcare chatbots, or virtual visit software, US7426730B2 is directly relevant to your freedom-to-operate position. This case demonstrates that the patent has been actively asserted against a commercial healthcare SaaS vendor’s full product suite, and that the defendant chose settlement over an invalidity challenge — suggesting claim scope may be non-trivial to design around or invalidate. R&D and product teams scaling HIPAA-compliant communication features should commission an FTO analysis before launch.
PatSnap Eureka’s FTO Search Agent can map the claim language of US7426730B2 against your product architecture, identify prior art that may inform invalidity arguments, and surface related family members or continuation risk. Eureka’s semantic claim analysis goes beyond keyword matching to assess functional overlap with secure messaging session management — helping IP counsel and product teams make faster, evidence-based clearance decisions without starting from scratch.
Run a freedom-to-operate analysis on US7426730B2 to assess your product’s exposure
Run FTO in Eureka →Similar Secure Healthcare Messaging Patent Cases in U.S. District Courts
Browse comparable patent infringement actions involving secure messaging and telehealth communication technology litigated in U.S. district courts, including the Northern District of Texas.
What this case signals for the healthcare communications IP landscape
A swift pre-trial settlement over core telehealth messaging functionality underscores rising patent risk for secure healthcare communication platforms.
Secure healthcare messaging is an active patent enforcement target
The breadth of accused products — texting, virtual visits, chatbots, telehealth platforms — signals that patent holders are mapping infringement claims broadly across healthcare SaaS stacks. Companies building or acquiring healthcare communication tools should conduct proactive FTO analysis against messaging and session-management patents before product launch or commercial scale-up.
Pre-trial settlement preserves the patent as a live enforcement asset
Because no claim construction or invalidity ruling was entered, US7426730B2 remains unadjudicated and potentially re-deployable against other defendants. Competitors of Qliqsoft operating in the same secure messaging or telehealth communication space should assess their exposure to this patent independently — they cannot rely on any ruling from this case.
Dav v Qliqsoft — key questions answered
Dav Sub asserted US7426730B2, a patent covering secure messaging and communication technology, filed under application number US10/125794. The patent was asserted against Qliqsoft’s secure texting, secure virtual visits, healthcare chatbot, and telehealth software platforms in the Northern District of Texas.
The case settled after approximately 342 days. Judge Kinkeade issued an administrative closure order on 16 October 2024 after being notified of the settlement, directing the parties to submit dismissal papers within 60 days. No damages figure or licensing terms are publicly disclosed; the settlement agreement is confidential.
Yes. Because the case settled before any claim construction, summary judgment, or trial ruling, no court has adjudicated the validity or enforceability of US7426730B2. The patent remains unadjudicated and potentially enforceable against other parties. Companies in the healthcare messaging space cannot rely on any ruling from this case to establish invalidity.
Dav Sub accused four Qliqsoft product lines: its secure texting platform, secure virtual visits service, secure healthcare chatbots, and secure telehealth software systems and platforms. The breadth of accused products suggests Dav Sub mapped its patent claims broadly across Qliqsoft’s entire healthcare communication portfolio.
The Northern District of Texas, particularly under judges like Ed Kinkeade, is a recognised patent-plaintiff-favoured venue with an established patent docket and efficient case management. Filing there typically accelerates timelines and increases early settlement pressure on defendants, consistent with the 342-day resolution in this case. The public record does not disclose a specific jurisdictional nexus beyond the plaintiff’s venue choice.
PatSnap Eureka searches patents and litigation data to answer instantly.